Here’s a question that doesn’t get enough attention in the peptide research community: who actually decides whether someone can access GLP-1 drugs?
The answer, increasingly, is not your doctor. It’s a telehealth platform your insurance company has a contract with.
NPR’s Sydney Lupkin reported this week on a growing tension in the United States between primary care physicians and the telehealth companies that are becoming middlemen for obesity drug prescriptions. The story highlights a structural shift in how GLP-1 medications are being prescribed and controlled - one that has implications well beyond the US market.
The Setup
The basic situation is this: GLP-1 drugs like semaglutide and tirzepatide are expensive. In the US, brand-name versions can cost over $1,000 per month without insurance. Insurance companies are understandably looking for ways to manage those costs.
One approach that’s gaining traction is to require patients to use specific telehealth platforms before their insurance will cover an obesity drug prescription. Instead of going to your regular GP and getting a prescription, you’re directed to an app or online service that assesses your eligibility and - if you qualify - provides the prescription.
On paper, this makes sense. Telehealth can be more efficient, can standardise assessment criteria, and can monitor patients remotely. But the NPR report suggests the reality is more complicated.
What the Doctors Are Saying
Primary care physicians are raising concerns about several aspects of this model:
Fragmented care. When your obesity drug prescription is managed by a telehealth company you’ve never met, your regular GP may not have full visibility into what you’re taking. Drug interactions, dose adjustments, and side effect management can fall through the cracks.
Financial incentives. Telehealth platforms that are paid by insurance companies to manage obesity drug prescriptions have a structural incentive to limit spending. Whether that translates to limiting prescriptions is a matter of debate, but the incentive exists.
Access barriers. Not everyone is comfortable using telehealth platforms. Older patients, people in rural areas with poor internet, and those with limited English proficiency may find these platforms harder to navigate than a face-to-face GP visit.
Continuity of care. Obesity is a chronic condition that benefits from ongoing management by a provider who knows your full medical history. Telehealth platforms, by design, tend to be transactional rather than relational.
The Australian Angle
While the NPR report focuses on the US, the dynamics it describes are relevant to Australia’s own GLP-1 landscape.
Australia’s TGA has approved semaglutide (Wegovy) and tirzepatide (Mounjaro) for specific indications. Access is through prescription, and the PBS does not currently cover these medications for obesity (only for type 2 diabetes in certain circumstances). This means Australians seeking GLP-1 drugs for weight management are paying out of pocket - typically $200-$400 per month depending on the compound and dose.
The Australian telehealth market for obesity medications is growing, with several platforms now offering consultations and prescriptions for GLP-1 compounds. While the insurance-driven gatekeeping model described in the NPR report doesn’t map directly to Australia (because most obesity drug costs are out-of-pocket), the broader question of who controls access is still relevant.
If telehealth becomes the primary channel for GLP-1 prescriptions in Australia, the same concerns about fragmented care and financial incentives could apply.
What the Research Says
The evidence on telehealth for obesity management is mixed. A 2024 systematic review published in Obesity Reviews found that telehealth interventions for weight management can be effective, particularly when combined with regular follow-up. However, the review also noted that telehealth is not equivalent to in-person care for all patients, and that digital literacy is a significant barrier.
The key question isn’t whether telehealth can work for obesity management. It can. The question is whether insurance-mandated telehealth is the right model for delivering care, or whether it’s primarily a cost-control mechanism dressed up as innovation.
The Access Problem
For the Grey Highway community, the access question has a specific dimension. Many people interested in peptide research compounds are navigating a landscape where:
- GPs may not be familiar with GLP-1 compounds or may be reluctant to prescribe them
- Telehealth platforms may offer convenience but limited depth of care
- Regulatory frameworks differ significantly between countries
- Cost remains a major barrier, particularly in Australia where PBS coverage is limited
The telehealth model described in the NPR report adds another layer to this: even if you have a willing doctor and the financial means to pay, your insurance (if you have it) may require you to go through a specific platform first.
Community Implications
This is a conversation worth having in the Australian peptide research community. As GLP-1 compounds become more mainstream and more accessible, the models through which they’re prescribed will evolve. Telehealth will almost certainly play a role - the question is what kind of role.
A few things worth watching:
- Australian telehealth regulation - how will the TGA and AHPRA approach telehealth prescribing for obesity medications?
- Insurance models - if private health insurers in Australia start covering GLP-1 drugs, will they follow the US model of mandating specific telehealth platforms?
- GP education - will Australian GPs become more comfortable prescribing GLP-1 compounds, or will the gap between GP knowledge and patient demand continue to widen?
- Community self-education - platforms like Grey Highway can play a role in helping people understand their options and navigate the system
The NPR report is a useful reminder that access to research compounds isn’t just a scientific question. It’s an economic, regulatory, and structural one. How these systems evolve will shape who gets access and on what terms.
This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.
Sources
- NPR: “Primary care doctors raise alarm as telehealth companies get involved in obesity drugs” (14 June 2026) by Sydney Lupkin - npr.org/sections/health
- Obesity Reviews: Systematic review of telehealth interventions for weight management (2024)
- TGA: Semaglutide and tirzepatide approved indications - tga.gov.au